Healthcare PharmaceuticalsRoche's HER2-targeted biologic (pertuzumab) developed by Genentech, FDA approved June 8, 2012, that targets a different HER2 domain than Herceptin and is used in combination with Herceptin and chemotherapy for HER2-positive breast cancer in both metastatic and early-stage settings.
oncologybreast-cancerher2